Sangamo Therapeutics (NASDAQ:SGMO) and Arsanis (NASDAQ:ASNS) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.
This is a breakdown of current ratings for Sangamo Therapeutics and Arsanis, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Sangamo Therapeutics currently has a consensus price target of $20.83, suggesting a potential upside of 48.81%. Arsanis has a consensus price target of $18.50, suggesting a potential upside of 1,034.97%. Given Arsanis’ higher probable upside, analysts plainly believe Arsanis is more favorable than Sangamo Therapeutics.
This table compares Sangamo Therapeutics and Arsanis’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Insider & Institutional Ownership
63.8% of Sangamo Therapeutics shares are held by institutional investors. Comparatively, 68.7% of Arsanis shares are held by institutional investors. 1.2% of Sangamo Therapeutics shares are held by company insiders. Comparatively, 50.9% of Arsanis shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Earnings and Valuation
This table compares Sangamo Therapeutics and Arsanis’ revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Sangamo Therapeutics||$36.57 million||38.92||-$54.56 million||($0.70)||-20.00|
Arsanis has lower revenue, but higher earnings than Sangamo Therapeutics. Sangamo Therapeutics is trading at a lower price-to-earnings ratio than Arsanis, indicating that it is currently the more affordable of the two stocks.
Arsanis beats Sangamo Therapeutics on 8 of the 12 factors compared between the two stocks.
About Sangamo Therapeutics
Sangamo Therapeutics, Inc. focuses on translating science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger DNA-binding protein (ZFP) technology enables specific genome editing and gene regulation. The ZFPs could be engineered to make ZFP nucleases (ZFNs), proteins that could be used to modify DNA sequences by adding or knocking out specific genes; and ZFP transcription factors (ZFP TFs), proteins that can be used to turn genes on or off. Its therapeutic products include SB-728-T, a ZFN-mediated autologous T-cell product for human immunodeficiency virus and acquired immunodeficiency syndrome (HIV/AIDS), which is in Phase II and I clinical trials; and SB-728-HSPC that is in Phase I/II clinical trials for HIV/AIDS. The company also engages in Phase I/II studies of in vivo genome editing applications of ZFP Therapeutics for Hemophilia B, Hemophilia A, and Mucopolysaccharidosis I (MPS) and MPS II, which are lysosomal storage disorder (LSD); preclinical programs in other LSDs; and research stage programs in central nervous system disorders and cancer immunotherapies. It has collaborative partnerships with Biogen Inc. to develop therapeutic genome editing products in hemoglobinopathies; and Shire International GmbH to develop preclinical development program in Huntington's disease, as well as license agreements with Sigma-Aldrich Corporation to develop laboratory research reagents and Dow AgroSciences, LLC to modify the protein expression of plant cells and plants. The company also has a research collaboration and license agreement with Pfizer Inc; and collaboration with Kite for developing ex vivo cell therapies in oncology. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was founded in 1995 and is headquartered in Richmond, California.
Arsanis, Inc., a clinical-stage biopharmaceutical company, focuses on applying monoclonal antibody (mAb) immunotherapies to address infectious diseases. Its lead product candidate is ASN100, a mAb therapeutic in Phase II clinical development for the prevention of staphylococcus aureus pneumonia in mechanically ventilated patients. The company's preclinical pipeline comprises mAbs targeting various bacterial and viral pathogens, including respiratory syncytial virus. Arsanis, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.
Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.